Clinical trial
Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities
NCT00403455 · VA Office of Research and Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00403455 |
|---|---|
| Title | Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities |
| Official title | Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities |
| Acronym | MTG |
| Lead sponsor | VA Office of Research and Development, U.S. Fed |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | PTSD |
| Intervention type | Drug |
| Interventions | Paroxetine |
| Enrollment | 38 |
| Start date | Oct 1, 2006 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Nov 23, 2006 |
| Last update posted | Jul 2, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: